Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

VX-135

- PMLiVE

Quality in Care Hepatitis C programme open for entry

PMGroup's QiC programme aims to recognise best practice in care for hepatitis C in the UK

- PMLiVE

BMS gives Erbitux rights to Lilly in the US

Firm wants to focus on its burgeoning PD-1 cancer range

- PMLiVE

Gilead under fire for Sovaldi anti-diversion policy

Accused as generic versions of the drug start to reach the market

- PMLiVE

Top biotech firms saw sales jump in 2014

But rate of growth slowing from the past five years according to new analysis

- PMLiVE

Merck’s Keytruda beats BMS’ Yervoy in melanoma face-off

Both firms competing for a leading share in the highly competitive skin cancer drug market

- PMLiVE

Cancer charity partners with research council for innovation

CRUK teams up with multi-disciplinary groups to help develop new oncology products

Seismic shifts: Hepatitis C and payers

How hep C is causing paradigm changes in payer behaviour

- PMLiVE

The end of hepatitis C?

Next-gen hep C therapies may see the disease's global elimination - but treament access must be stepped up dramatically

- PMLiVE

Hepatitis C drugs drive US drug costs up in 2014

Played a role in a 13% increase in US prescription spending

- PMLiVE

NICE recommends BMS and Pfizer’s Eliquis for blood clots

Will be a treatment option for venous thromboembolism

Bristol-Myers Squibb (BMS) building

BMS signs $975m deal for Bavarian Nordic cancer vaccine

Furthers prominent position in immuno-oncology with Prostvac

- PMLiVE

Sovaldi-Daklinza combo cures hep C in co-infected HIV patients

Phase III trial of BMS and Gilead antivirals cured 97% of patients

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links